Final report of University Hospital Hradec Kralove to the clinical trial protocol no. B1971033

Abstract

A duration fo Immunity Study, to Assess Persistence of hSBA response for up to 48 Months after completion of Vaccination with bivalent rLP2086 Vaccine

Keywords

• rLP2086
• hSBA